Stability of a reconstituted peptide is a function of three degradation pathways running in parallel: hydrolytic cleavage of peptide bonds (temperature- and pH-dependent), deamidation at asparagine and glutamine residues (accelerates in aqueous solution), and aggregation — collapse of the tertiary structure producing dimers and higher-order species that lose receptor affinity. All three pathways obey Arrhenius kinetics: a 10 °C rise in storage temperature roughly doubles the rate of each.
Refrigerated storage (2–8 °C)
Most research peptides hold 4–6 weeks in bacteriostatic water at standard refrigerator temperature: BPC-157, TB-500, Ipamorelin, GHRP-2/6, CJC-1295, Hexarelin, Sermorelin, Tesamorelin. The 4–6 week ceiling reflects the composite of all three degradation pathways — measured activity at 6 weeks is typically 75–85% of fresh.
Exceptions that run shorter:
- Somatropin (HGH) in bacteriostatic water: 14–21 days. The 191-residue protein has multiple oxidation-sensitive methionine residues and specific deamidation hotspots at positions 149 and 152.
- MGF (mechano-growth factor) and TB-500 fragment variants: 2–3 weeks. The IGF-1 analogue structure is particularly prone to disulfide scrambling in aqueous solution.
- GLP-1 agonists (semaglutide, tirzepatide): 4 weeks at refrigerator temperature; the pharmacy pen formulations use proprietary stabilisers not present in lyophilised research preparations, and the “28-day after first use” rule on prescription pens is the data-backed number for similar aqueous formulations.
Frozen storage (−20 °C)
Freezing shifts the kinetic slowdown from Arrhenius into nearly-arrested territory — peptide stability extends from weeks to months. Refrigerated 4–6 weeks becomes frozen 3–6 months for most compounds. The catch is freeze-thaw damage: ice crystal nucleation disrupts hydrogen bonding in the protein folded state and mechanically stresses tertiary structure. Each thaw cycle loses measurable activity; repeated cycles compound the loss.
Aliquoting protocol:
- Reconstitute the full vial as normal. Solution should be clear within 3 minutes of gentle swirling.
- Using sterile insulin syringes, draw aliquots sized to one week of use. A 10 mg vial reconstituted in 2 mL dosed at 300 mcg/day = 1.5 mL/week consumption → three 0.5 mL aliquots + one keep-vial portion.
- Cap the syringes (original needle cover, or a small sterile cap).
- Freeze the aliquots you will not use this week at −20 °C. Keep one aliquot in the refrigerator for active use.
- Thaw each frozen aliquot once. Use within 5–7 days of thawing. Do not re-freeze a thawed aliquot.
This converts a 4-week refrigerated usability window into a 12–16 week practical window from a single reconstitution, with activity loss per aliquot within 5–10% of fresh-reconstituted baseline.
Degradation markers — signs the peptide is compromised
- Cloudiness in a previously clear solution. Aggregation in progress; activity already partially lost.
- Visible particulate. Either aggregation has advanced to visible precipitate or contamination is present. Either case warrants discard, not filtration.
- Colour change. Yellow tint indicates oxidation at methionine or tryptophan residues. Pink or red hue suggests bacterial or fungal contamination.
- Loss of clinical effect at established dose. Subjective markers (GH-secretagogue-induced tingling, hunger response, water retention on HGH) diminishing across the vial’s use indicates progressive degradation. Confirmable on IGF-1 bloodwork for HGH and secretagogues.
When in doubt, discard. A replacement vial costs less than the cost of an injection-site abscess, a failed protocol cycle, or the accumulated opportunity cost of running degraded peptide expecting full effect.